Two Pediatric Bone Disorders in the Era of Disease Specific Therapies – When to Refer Patients and How to Treat XLH and HPP

Faculty

FACULTY_NAME
Jill H. Simmons, MD
Dr. Jill Simmons is a Professor of Pediatrics in the Ian M. Burr Division of Pediatric Endocrinology and Diabetes at Vanderbilt University Medical Center. She is the founder and director of the Vanderbilt Program for Pediatric Metabolic Bone Disease.

Dr. Simmons is an investigator of clinical trials on novel therapies for metabolic bone diseases in children. She authored numerous publications on the diagnosis and treatment of diseases including hypophosphatasia and X-linked hypophosphatemia. She serves as a regular reviewer for Diabetes Care, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Investigation, Pediatric Blood and Cancer, and Pediatric Diabetes.

FACULTY_NAME
Eric T. Rush, MD
Dr. Eric Rush is a Clinical Geneticist at Children’s Mercy Hospital and an Associate Professor of Pediatrics at the University of Missouri-Kansas City. He is the co-director of the Children’s Mercy Skeletal Dysplasia clinic.

Dr. Rush’s clinical and research interests include hypophosphatasia and X-linked hypophosphatemia, among others. Topics of his publications ranged from molecular characterization, skeletal pathology, to best practice of using novel therapies in rare genetic diseases. Dr. Rush is board certified in Pediatrics, Internal Medicine and Clinical Genetics. He is on the Scientific Advisory Board for the Rare Bone Diseases Alliance.